Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 8/20 | 0.57 |
| ▸ | EGFR | P00533 | 3/20 | 0.57 |
| ▸ | TDO2 | P48775 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | GSK3B | P49841 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8999189 | 0.92 | IDO1 (0.55) | IDO1EGFRTDO2MAPTKDM4E | |
| SCHEMBL8999062 | 0.86 | MAPT (0.56) | IDO1EGFRTDO2MAPTKDM4E | |
| SCHEMBL8998987 | 0.85 | EGFR (0.72) | IDO1EGFRTDO2MAPTKDM4E | |
| SCHEMBL1388675 | 0.84 | EGFR (0.75) | IDO1EGFRTDO2MAPTHTT | |
| SCHEMBL5380593 | 0.82 | EGFR (0.70) | IDO1EGFRTDO2MAPTKDM4E | |
| SCHEMBL10789931 | 0.81 | IDO1 (0.69) | IDO1EGFRTDO2MAPTKDM4E | |
| SCHEMBL3201173 | 0.81 | EGFR (0.65) | IDO1EGFRTDO2MAPTKDM4E | |
| SCHEMBL2260925 | 0.79 | IDO1 (0.64) | IDO1EGFRTDO2MAPTKDM4E | |
| Oxindole SCHEMBL3201159 | 0.77 | EGFR (0.57) | IDO1EGFRTDO2MAPTKDM4E | |
| SCHEMBL29062879 | 0.77 | LMNA (0.58) | EGFRHTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4582909-A | Benzobicyclic lactam acids and derivatives as cognition activators | WARNER-LAMBERT COMPANY (US) | 1986-04-15 | — | — | US | claimed |
| EP-0151539-A2 | Benzobicyclic lactam acids, their derivatives, an intermediate in the preparation thereof and processes for the production thereof | WARNER-LAMBERT COMPANY (US) | 1985-08-14 | — | — | EP | claimed |
| EP-3138841-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2017-03-08 | — | — | EP | disclosed |
| US-9156840-B2 | D2 antagonists, methods of synthesis and methods of use | Altos Therapeutics, LLC (US) | 2015-10-13 | — | — | US | disclosed |
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-11-27 | — | — | US | disclosed |
| EP-2582701-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC | 2012-01-12 | — | — | US | disclosed |
| WO-2011160084-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | Altos Therapeutics, LLC (US) | 2011-12-22 | — | — | WO | disclosed |
| US-5556874-A | ENZYME INHIBITORS AS ANTICARCINOGENIC AGENTS | WARNER LAMBERT COMPANY (US) | 1996-09-17 | — | — | US | disclosed |
| US-5464861-A | Anticarcinogenic agents | WARNER-LAMBERT (US) | 1995-11-07 | — | — | US | disclosed |
| EP-0654024-A1 | 2-THIOINDOLES (SELENOINDOLES) AND RELATED DISULFIDES (SELENIDES) WHICH INHIBIT PROTEIN TYROSINE KINASES AND WHICH HAVE ANTITUMOR PROPERTIES | WARNER-LAMBERT COMPANY (US) | 1995-05-24 | — | — | EP | disclosed |
| WO-1994003427-A1 | 2-THIOINDOLES (SELENOINDOLES) AND RELATED DISULFIDES (SELENIDES) WHICH INHIBIT PROTEIN TYROSINE KINASES AND WHICH HAVE ANTITUMOR PROPERTIES | WARNER-LAMBERT COMPANY (US) | 1994-02-17 | — | — | WO | disclosed |
| US-4677112-A | 1,2,3,4-tetrahydro-2-oxo-8-quinolineacetic and -propanoic acids and derivatives as cognition activators | WARNER-LAMBERT COMPANY (US) | 1987-06-30 | — | — | US | disclosed |
| US-4582909-A | Benzobicyclic lactam acids and derivatives as cognition activators | WARNER-LAMBERT COMPANY (US) | 1986-04-15 | — | — | US | disclosed |
| EP-0151539-A2 | Benzobicyclic lactam acids, their derivatives, an intermediate in the preparation thereof and processes for the production thereof | WARNER-LAMBERT COMPANY (US) | 1985-08-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350005-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | DRD2, DRD3, AVPR2 | IDO1 644/4885EGFR 705/4885TDO2 622/4885 |
| US-20120010228-A1 | D2 ANTAGONISTS, METHODS OF SYNTHESIS AND METHODS OF USE | DRD2, DRD3, AVPR2 | IDO1 644/4885EGFR 705/4885TDO2 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.